NCT05293405 is a NA clinical trial of 18F-DPA-714 PET in Autoimmune Encephalomyelitis, sponsored by Ruijin Hospital.

Who is sponsoring NCT05293405?

NCT05293405 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT05293405?

Interventions in NCT05293405: 18F-DPA-714 PET.

What condition does NCT05293405 study?

NCT05293405 studies Autoimmune Encephalomyelitis.

Is NCT05293405 still recruiting?

NCT05293405 is currently status unknown. Last updated 18 April 2023.

Last reviewed 2023-04-18 · How we verify

NCT05293405

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuroinflammatory PET Imaging in Autoimmune Encephalomyelitis

Status unknown NA Last updated 18 April 2023

What this trial tests

NA trial testing 18F-DPA-714 PET in Autoimmune Encephalomyelitis in 100 participants. Status unknown.

Timeline

14 December 2021

Primary endpoint
13 December 2023

31 December 2024

Quick facts

Lead sponsor	Ruijin Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	14 December 2021
Primary completion	13 December 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

18F-DPA-714 PET

Conditions studied

Autoimmune Encephalomyelitis — all drugs for Autoimmune Encephalomyelitis →

Sponsor

Ruijin Hospital

Who can join

Adults 16 to 80, any sex, with Autoimmune Encephalomyelitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Autoimmune encephalomyelitis is a heterogeneous group of central nervous system (CNS) autoimmune diseases characterized by the production of anti-neuron-associated autoantibodies which target neuronal surface proteins, synaptic receptors and intracellular antigens. MRI, as a current first-line imaging tool of CNS inflammation, is difficult to diagnose them because the majority of patients have normal MRI images, and only a few may show local signal or structural abnormalities (including inflammation, edema, or atrophy). The 18 kDa translocator protein (TSPO) expression in the CNS is upregulated in response to microglia activation. DPA-714 is high affinity for binding to TSPO, making 18F-labeled DPA-714 (18F-DPA-714) PET a very promising diagnostic imaging tool for neuroinflammation in patients with autoimmune encephalomyelitis.This study aims to explore the value of 18F-DPA-714 PET in the early diagnosis, therapeutic assessment and prognosis in patients with autoimmune encephalomyelitis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Microglial Activation Imaging Using <sup>18</sup>F-DPA-714 PET/MRI for Detecting Autoimmune Encephalitis.
Zhang M, Meng H, Zhou Q, Chunyu H, et al · · 2024 · cited 22× · PMID 38441089 · DOI 10.1148/radiol.230397
TSPO Radioligands for Neuroinflammation: An Overview.
Salerno S, Viviano M, Baglini E, Poggetti V, et al · · 2024 · cited 16× · PMID 39275061 · DOI 10.3390/molecules29174212
<sup>18</sup>F-DPA714 PET/MRI as a potential imaging tool for detecting possible antibody-negative autoimmune encephalitis: a prospective study.
Meng H, He L, Chunyu H, Zhou Q, et al · · 2024 · cited 3× · PMID 39294471 · DOI 10.1007/s00415-024-12690-w

Verify or expand the search:

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05293405 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 18 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05293405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing